



#### **CERTIFICATE OF ANALYSIS**

# HUMAN CRYOPRESERVED HEPATOCYTES GRADE **P**, QUALIFIED FOR **P**LATEABLE ASSAYS

Catalog number: PR-LIV-P Batch number: HEP187730

FOR RESEARCH USE ONLY. Not intended for human or animal diagnostic or therapeutic uses. HUMAN CRYOPRESERVED HEPATOCYTES are not recommended for expanding. Human primary cells must be treated as potential pathogens. Users need to wear personal protective equipment during the work. DO NOT USE DRY ICE DURING WORK, STORAGE, OR TRANSPORTATION.

## 1. BIOLOGICAL MATERIAL 1.1. INFORMATION ABOUT DONOR

Age Sex	71 years			
	Male Fema	ale 🔾		
Ethnicity	Caucasian	African 🔘	Not available 🔾	
Pathology or	Hemorrhagic str	oke		
Cause of death				
Patient	Diabetes	Yes 🔾	No 🗨	Unknown 🔘
information	Heart disease	Yes	No 🔾	Unknown 🔾
	High blood	Yes 🗨	No 🔾	Unknown 🔘
	pressure			_
	Smoking	Yes 🔾	No 🗨	Unknown 🔘
	Alcoholism	Yes 🔾	No 🗨	Unknown 🔾
	Medication:	-		

Biological materials were collected from the certified clinical hospitals. Clinical site provided ethical committee approval and conducted the collection in accordance to the Directive 2004/23/EC of the European Parliament

#### 1.2. SAFETY DATA

Virological status	Specification	Result	
Hepatitis B (HBs antigen, anti HBc antibody)		Positive (	Negative
Hepatitis C (anti HCV antibody)	Negative	Positive 🔾	Negative 🗨
HIV-1 and HIV-2 (anti HIV-1 and HIV-2 antibodies)		Positive (	Negative

#### 1.3. LIVER TESTS

Name	Result	Reference
Alanine Aminotransferase (ALT)	37	4-42 U/I
Aspartate Aminotransferase (AST)	34	4-42 U/I
Gamma-Glutamyl Transferase (GGT)	74	5-61 U/l
Creatinine	98	48-108 uM/l





Total bilirubin	15.4	5-21 uM/l
Total protein	60	57-82 g/l

### 2. PRODUCT DESCRIPTION

Process	Human hepatocytes were isolated and frozen by standard methods.
Biosafety level	Human sourced products handled at the Biological Safety Level 2.
Date of production	15/11/2023
Cell quality control	17/11/2023
date	
Packaging	0.5 mL suspension in the cryovial with a minimum of 8x106 viable cells.


## 3. CELL QUALITY CONTROL AFTER THAWING

Criteria	Specification	Result	CONCLU	JSION
Post-thaw viability	≥ 80%	88 %	Yes	No 🔾
Number of viable cells per vial	≥ 8 x 106	9,5 x 106	Yes	No 🔾
Optimal Percoll concentration	25-28%	28 %	Yes	No 🔾
Cell confluence in 20- 24 h of cultivation on collagen I coated plate	≥ 70%	85%	Yes	No 🔾
The ability of spheroids formation	Yes	Yes	Yes	No 🔾
Total protein test	250 μg/cm²	300 µg/cm²	Yes	No 🔾
Microbial sterility	No microbial growth detectable	Undetectable	Yes	No 🔾
Mycoplasma contamination	Standard test kit	Undetectable	Yes •	No 🔾





## 4. MICROPHOTOGRAPH



24-hours of cultivation, 200x magnification

(IdMOC, Cat #71034)
plement + 1% Penicillin/Streptomycin

#### 5. METABOLIC ACTIVITY

Substrate	Intrinsic Clearance (μL/min/10 <sup>6</sup> cells)	Enzymes Responsible for Metabolism
Dextromethorphan		CYP2D6 > 3A/2C19
Diclofenac		CYP2C9, UGT2B7, UGT1A9
Verapamil		CYP3A4
4-Hydroxycoumarin		Phase II
Propranolol		CYP2D6 >1A2/2C19/UGT





Imipramine	CYP2D6/1A2/2C19/3A/ UGT1A4
Raloxifene	CYP3A
Midazolam	CYP3A4
4-methylumbelliferone	UGT1A6/9
Tolbutamide	CYP2C
Ketoprofen	UGT2B7

## 6. CELL STORAGE

Delivery	In liquid nitrogen, ≤ 150°C
Storage temperature	In vapour of liquid nitrogen, ≤ 150°C up to 5years

### 7. VISA FOR BATCH RELEASE

Name	Signature	Date	
Tetiana Papurina		17/11/2023	